{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:45:40Z","timestamp":1782506740134,"version":"3.54.5"},"reference-count":126,"publisher":"American Veterinary Medical Association (AVMA)","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2026,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bedinvetmab (Librela\/Beransa) is a canine anti\u2013nerve growth factor monoclonal antibody (aNGFmAb) approved for the management of osteoarthritis pain. By neutralizing NGF, it reduces nociceptive signaling and improves comfort. However, NGF plays critical roles in neural, bone, and cartilage homeostasis across species. Multiple studies indicate that NGF contributes to bone remodeling and cartilage repair by modulating osteoblast, osteoclast, and chondrocyte activity, processes that are highly active in osteoarthritic joints. In humans, rodents, and rabbits, inhibition of NGF is associated with rapidly progressive osteoarthritis, a serious adverse event characterized by accelerated joint destruction and collapse, which ultimately prevented regulatory approval of human aNGFmAbs\u2014yet the canine aNGFmAb, bedinvetmab, received marketing authorization. Emerging clinical signals in canine patients raise concern that NGF blockade may similarly mask early structural deterioration, potentially accelerating osteolysis and chondrolysis in both index joints and nonindex joints. Although purportedly rare, those adverse drug events are irreversible and often catastrophic, resulting in rapid joint degeneration, progressive osseous collapse, and fractures, which can occur within months. This stands in contrast to high reported clinician satisfaction rates and underscores the need for careful postmarketing vigilance. Given NGF\u2019s integral role in joint biology, objective monitoring strategies are warranted. These strategies should include thorough baseline and follow-up examinations, standardized imaging protocols, diligent adverse event reporting, and, where appropriate, histopathological assessment. Transparent communication of potential risks, along with documented informed consent, is essential to support balanced, clinical decision-making by veterinarians and pet owners.<\/jats:p>","DOI":"10.2460\/javma.26.03.0170","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:45:52Z","timestamp":1782503152000},"page":"1-11","source":"Crossref","is-referenced-by-count":0,"title":["Bedinvetmab (Librela\/Beransa) in dogs raises safety concerns, including rapidly progressive osteoarthritis, and warrants vigilant adverse event reporting"],"prefix":"10.2460","author":[{"given":"Dirsko J. F.","family":"von Pfeil","sequence":"first","affiliation":[{"name":"Small Animal Surgery Locum, Dallas, TX"},{"name":"Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4544-1234","authenticated-orcid":true,"given":"Robert J.","family":"Adams","sequence":"additional","affiliation":[{"name":"Veterinary Specialists of Sydney, Miranda, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Clark","sequence":"additional","affiliation":[{"name":"Davies Veterinary Specialists, Shillington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-8835","authenticated-orcid":true,"given":"Curtis W.","family":"Dewey","sequence":"additional","affiliation":[{"name":"Elemental Pet Vets, Freeville, NY"},{"name":"Global Pet Project, Freeville, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-0001","authenticated-orcid":true,"given":"Matthew W.","family":"Brunke","sequence":"additional","affiliation":[{"name":"Elemental Pet Vets, Freeville, NY"},{"name":"Hayashi Laboratory, College of Veterinary Medicine, Cornell University, Ithaca, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Garner","sequence":"additional","affiliation":[{"name":"CatsOnly, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto I.","family":"Lanz","sequence":"additional","affiliation":[{"name":"Spry Companions Veterinary Orthopedic Specialists, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nate","family":"Miller","sequence":"additional","affiliation":[{"name":"Spry Companions Veterinary Orthopedic Specialists, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5046-4213","authenticated-orcid":true,"given":"Lee","family":"Breshears","sequence":"additional","affiliation":[{"name":"Spry Companions Veterinary Orthopedic Specialists, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc M.","family":"D\u00e9jardin","sequence":"additional","affiliation":[{"name":"Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5496-4127","authenticated-orcid":true,"given":"Andrew","family":"Armitage","sequence":"additional","affiliation":[{"name":"Greenside Referrals, Greenside Veterinary Practice, Melrose, Roxburghshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Hayashi Laboratory, College of Veterinary Medicine, Cornell University, Ithaca, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2837-7822","authenticated-orcid":true,"given":"Aldo","family":"Vezzoni","sequence":"additional","affiliation":[{"name":"Clinica Veterinaria Vezzoni, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"Vet J","first-page":"105733","article-title":"Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs","volume":"276","author":"Krautmann M","year":"2021","unstructured":"Krautmann M, Walters R, Cole P,  Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. Vet J. 2021;276:105733. doi:10.1016\/j.tvjl.2021.105733"},{"key":"ref2","series-title":"Front Vet Sci","first-page":"1502218","article-title":"A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis","volume":"12","author":"Innes JF","year":"2025","unstructured":"Innes JF, Lascelles BDX, Bell D,  A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. Front Vet Sci. 2025;12:1502218. doi:10.3389\/fvets.2025.1502218"},{"issue":"15","key":"ref3","series-title":"Animals (Basel)","first-page":"2231","article-title":"Use of Bedinvetmab (Librela) for canine osteoarthritis in France, Germany, Italy, Spain, and the UK: quantitative analysis of veterinarian satisfaction and real-world treatment patterns","volume":"14","author":"Gildea E","year":"2024","unstructured":"Gildea E, North C, Walker K, Adriaens F, Lascelles BDX. Use of Bedinvetmab (Librela) for canine osteoarthritis in France, Germany, Italy, Spain, and the UK: quantitative analysis of veterinarian satisfaction and real-world treatment patterns. Animals (Basel). 2024;14(15):2231. doi:10.3390\/ani14152231"},{"issue":"3","key":"ref4","series-title":"Curr Neuropharmacol","first-page":"294","article-title":"Nerve growth factor: a focus on neuroscience and therapy","volume":"13","author":"Aloe L","year":"2015","unstructured":"Aloe L, Rocco ML, Balzamino BO, Micera A. Nerve growth factor: a focus on neuroscience and therapy. Curr Neuropharmacol. 2015;13(3):294\u2013303. doi:10.2174\/1570159X13666150403231920"},{"issue":"1","key":"ref5","series-title":"J Transl Med","first-page":"239","article-title":"Nerve growth factor: from the early discoveries to the potential clinical use","volume":"10","author":"Aloe L","year":"2012","unstructured":"Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. 2012;10(1):239. doi:10.1186\/1479-5876-10-239"},{"issue":"6781","key":"ref6","series-title":"Science","first-page":"eadr9608","article-title":"Mapping somatosensory afferent circuitry to bone identifies neurotrophic signals required for fracture healing","volume":"391","author":"Xu M","year":"2026","unstructured":"Xu M, Li Z, Thottappillil N,  Mapping somatosensory afferent circuitry to bone identifies neurotrophic signals required for fracture healing. Science. 2026;391(6781):eadr9608. doi:10.1126\/science.adr9608"},{"issue":"1","key":"ref7","series-title":"Nat Commun","first-page":"3225","article-title":"Nerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints","volume":"15","author":"Zhao L","year":"2024","unstructured":"Zhao L, Lai Y, Jiao H, Huang J. Nerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints. Nat Commun. 2024;15(1):3225. doi:10.1038\/s41467-024-47633-6"},{"issue":"suppl 1","key":"ref8","series-title":"Osteoarthritis Cartilage","first-page":"S18","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23","author":"Hochberg MC","year":"2015","unstructured":"Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015;23(suppl 1):S18\u2013S21. doi:10.1016\/j.joca.2014.10.005"},{"issue":"1","key":"ref9","series-title":"Ann Rheum Dis","first-page":"295","article-title":"Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model","volume":"76","author":"LaBranche TP","year":"2017","unstructured":"LaBranche TP, Bendele AM, Omura BC,  Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Ann Rheum Dis. 2017;76(1):295\u2013302. doi:10.1136\/annrheumdis-2015-208913"},{"key":"ref10","series-title":"Front Physiol","first-page":"1201328","article-title":"Anti-NGF treatment worsens subchondral bone and cartilage measures while improving symptoms in floor-housed rabbits with osteoarthritis","volume":"14","author":"Menges S","year":"2023","unstructured":"Menges S, Michaelis M, Kleinschmidt-D\u00f6rr K. Anti-NGF treatment worsens subchondral bone and cartilage measures while improving symptoms in floor-housed rabbits with osteoarthritis. Front Physiol. 2023;14:1201328. doi:10.3389\/fphys.2023.1201328"},{"key":"ref11","article-title":"Joint meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee. Meeting transcript","year":"2021","unstructured":"US FDA. Joint meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee. Meeting transcript. March 25, 2021. Accessed February 2, 2026. http:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/referrals\/librela"},{"issue":"3","key":"ref12","series-title":"J Orthop","first-page":"260","article-title":"Overlapping features of rapidly progressive osteoarthrosis and Charcot arthropathy","volume":"16","author":"Sono T","year":"2019","unstructured":"Sono T, Meyers CA, Miller D, Ding C, McCarthy EF, James AW. Overlapping features of rapidly progressive osteoarthrosis and Charcot arthropathy. J Orthop. 2019;16(3):260\u2013264. doi:10.1016\/j.jor.2019.02.015"},{"issue":"1","key":"ref13","series-title":"Arthritis Res Ther","first-page":"78","article-title":"Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study","volume":"24","author":"Neogi T","year":"2022","unstructured":"Neogi T, Hunter DJ, Churchill M,  Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study. Arthritis Res Ther. 2022;24(1):78. doi:10.1186\/s13075-022-02759-0"},{"issue":"2","key":"ref14","series-title":"Arthritis Rheumatol","first-page":"382","article-title":"When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program","volume":"68","author":"Hochberg MC","year":"2016","unstructured":"Hochberg MC, Tive LA, Abramson SB,  When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 2016;68(2):382\u2013391. doi:10.1002\/art.39492"},{"issue":"4","key":"ref15","series-title":"Arthritis Rheumatol","first-page":"763","article-title":"Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase II randomized, double-blind, placebo-controlled extension study","volume":"69","author":"Sanga P","year":"2017","unstructured":"Sanga P, Katz N, Polverejan E,  Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase II randomized, double-blind, placebo-controlled extension study. Arthritis Rheumatol. 2017;69(4):763\u2013773. doi:10.1002\/art.39943"},{"key":"ref16","article-title":"Joint meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee. Meeting transcript","year":"2021","unstructured":"US FDA. Joint meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee. Meeting transcript. March 24, 2021. Accessed May 9, 2026. https:\/\/www.fda.gov\/media\/150662\/download"},{"key":"ref17","series-title":"Front Vet Sci","first-page":"1581490","article-title":"Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)","volume":"12","author":"Farrell M","year":"2025","unstructured":"Farrell M, Waibel FWA, Carrera I,  Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1581490. doi:10.3389\/fvets.2025.1581490"},{"issue":"2","key":"ref18","series-title":"Vet Anaesth Analg","first-page":"263","article-title":"A case of potential rapidly progressing osteoarthritis in a dog during bedinvetmab treatment","volume":"52","author":"Iff I","year":"2025","unstructured":"Iff I, Hohermuth B, Bass D, Bass M. A case of potential rapidly progressing osteoarthritis in a dog during bedinvetmab treatment. Vet Anaesth Analg. 2025;52(2):263\u2013265. doi:10.1016\/j.vaa.2024.11.041"},{"key":"ref19","series-title":"Front Vet Sci","first-page":"1640217","article-title":"Rapidly progressive osteoarthritis (RPOA) in companion animals treated with bedinvetmab (Librela): an expected pathophysiological phenomenon or a cause for concern?","volume":"12","author":"Mobasheri A","year":"2025","unstructured":"Mobasheri A, Hanson P, Larkin J. Rapidly progressive osteoarthritis (RPOA) in companion animals treated with bedinvetmab (Librela): an expected pathophysiological phenomenon or a cause for concern? Front Vet Sci. 2025;12:1640217. doi:10.3389\/fvets.2025.1640217"},{"key":"ref20","article-title":"Identification of Librela associated adverse joint events","author":"Armitage A","unstructured":"Armitage A. Identification of Librela associated adverse joint events. Poster presented at: Annual Meeting of the Veterinary Osteoarthritis Alliance; May 21-22, 2025; Loughborough, UK. Accessed May 9, 2026. https:\/\/www.stemcellsscotland.co.uk\/images\/content\/publications\/librela-adverse-reactions.png"},{"issue":"3","key":"ref21","series-title":"Vet Comp Orthop Traumatol","first-page":"157","article-title":"Emerging signs of rapidly progressive arthritic changes in dogs and cats receiving bedinvetmab and frunevetmab","volume":"39","author":"von Pfeil DJF","year":"2026","unstructured":"von Pfeil DJF, Armitage A, Nelson NC. Emerging signs of rapidly progressive arthritic changes in dogs and cats receiving bedinvetmab and frunevetmab. Vet Comp Orthop Traumatol. 2026;39(3):157\u2013161. doi:10.1055\/a-2846-8347"},{"key":"ref22","series-title":"Meeting transcript","article-title":"Arthritis Advisory Committee (AAC) Meeting","year":"2012","unstructured":"US FDA. Arthritis Advisory Committee (AAC) Meeting. Meeting transcript. March 12, 2012. Accessed June 26, 2024. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM307880"},{"key":"ref23","article-title":"Further characterization of a potential musculoskeletal syndrome associated with bedinvetmab in dogs: results from a surgeon questionnaire","author":"Lee BT","unstructured":"Lee BT, Fox DB. Further characterization of a potential musculoskeletal syndrome associated with bedinvetmab in dogs: results from a surgeon questionnaire. Abstract presented at: Annual Veterinary Orthopedic Society Conference; March 14-21, 2026; Big Sky, Montana. Conference proceedings: 10."},{"key":"ref24","article-title":"Dear veterinarian letter notifying veterinarians about adverse events reported in dogs treated with Librela (bedinvetmab injection)","unstructured":"US FDA. Dear veterinarian letter notifying veterinarians about adverse events reported in dogs treated with Librela (bedinvetmab injection). Accessed May 9, 2026. https:\/\/www.fda.gov\/animal-veterinary\/product-safety-information\/dear-veterinarian-letter-notifying-veterinarians-about-adverse-events-reported-dogs-treated-librela"},{"key":"ref25","article-title":"List of changes to combined VeDDRA list of clinical terms","author":"European Medicines Agency","unstructured":"European Medicines Agency. List of changes to combined VeDDRA list of clinical terms. Accessed May 9, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/list-changes-combined-veterinary-dictionary-drug-regulatory-activities-veddra-list-clinical-terms-reporting-suspected-adverse-events-animal-humans-veterinary-medicinal-products-2025_en.pdf"},{"key":"ref26","article-title":"Beransa canine injections-updated labels","author":"Australian Pesticides and Veterinary Medicines Authority","unstructured":"Australian Pesticides and Veterinary Medicines Authority. Beransa canine injections-updated labels. Accessed May 9, 2026. https:\/\/www.apvma.gov.au\/news-and-publications\/statements\/beransa-canine-injections-updated-labels?utm_source=APVMA+Newsletters+and+Communications&utm_campaign=12de21248a-news-update-250808&utm_medium=email&utm_term=0_a025640240-12de21248a-194797373"},{"issue":"16","key":"ref27","series-title":"N Engl J Med","first-page":"1521","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee","volume":"363","author":"Lane NE","year":"2010","unstructured":"Lane NE, Schnitzer TJ, Birbara CA,  Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363(16):1521\u20131531. doi:10.1056\/NEJMoa0901510"},{"issue":"1","key":"ref28","series-title":"Anesthesiology","first-page":"189","article-title":"Antagonism of nerve growth factor-TrkA signaling and the relief of pain","volume":"115","author":"Mantyh PW","year":"2011","unstructured":"Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL, Warner DS. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115(1):189\u2013204. doi:10.1097\/ALN.0b013e31821b1ac5"},{"issue":"12","key":"ref29","series-title":"Osteoarthritis Cartilage","first-page":"1612","article-title":"Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab","volume":"31","author":"Carrino JA","year":"2023","unstructured":"Carrino JA, McAlindon TE, Schnitzer TJ,  Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab. Osteoarthritis Cartilage. 2023;31(12):1612\u20131626. doi:10.1016\/j.joca.2023.08.010"},{"key":"ref30","series-title":"Ther Adv Musculoskelet Dis","first-page":"1759720x231171768","article-title":"Role of imaging for eligibility and safety of a-NGF clinical trials","volume":"15","author":"Roemer FW","year":"2023","unstructured":"Roemer FW, Hochberg MC, Carrino JA,  Role of imaging for eligibility and safety of a-NGF clinical trials. Ther Adv Musculoskelet Dis. 2023;15:1759720x231171768. doi:10.1177\/1759720X231171768"},{"issue":"9","key":"ref31","series-title":"Pain","first-page":"2068","article-title":"Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety","volume":"161","author":"Markman JD","year":"2020","unstructured":"Markman JD, Bolash RB, McAlindon TE,  Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain. 2020;161(9):2068\u20132078. doi:10.1097\/j.pain.0000000000001928"},{"issue":"12","key":"ref32","series-title":"Clin J Pain","first-page":"914","article-title":"Relative efficacy and safety of tanezumab for osteoarthritis: a systematic review and meta-analysis of randomized-controlled trials","volume":"37","author":"Zhang B","year":"2021","unstructured":"Zhang B, Tian X, Qu Z, Liu J, Yang L. Relative efficacy and safety of tanezumab for osteoarthritis: a systematic review and meta-analysis of randomized-controlled trials. Clin J Pain. 2021;37(12):914\u2013924. doi:10.1097\/AJP.0000000000000986"},{"issue":"3","key":"ref33","series-title":"Vet Anaesth Analg","first-page":"371","article-title":"A case of potential rapidly progressing osteoarthritis (RPOA) in a dog during bedinvetmab treatment. Veterinary Anaesthesia and Analgesia. 2024 Nov 29. Letter","volume":"52","author":"Farrell M","year":"2025","unstructured":"Farrell M, Adams R, Clark L. Iff I, Hohermuth B, Bass D, Bass M. A case of potential rapidly progressing osteoarthritis (RPOA) in a dog during bedinvetmab treatment. Veterinary Anaesthesia and Analgesia. 2024 Nov 29. Letter. Vet Anaesth Analg. 2025;52(3):371\u2013372. doi:10.1016\/j.vaa.2025.02.013"},{"key":"ref34","article-title":"CVM GFI #185 (VICH GL43): Target animal safety for veterinary pharmaceutical products","unstructured":"US FDA. CVM GFI #185 (VICH GL43): Target animal safety for veterinary pharmaceutical products. Accessed May 9, 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-185-vich-gl43-target-animal-safety-veterinary-pharmaceutical-products"},{"key":"ref35","author":"Freedom of Information summary: original new animal drug application\u2014MELOXIDYL (meloxicam) oral suspension","unstructured":"Freedom of Information summary: original new animal drug application\u2014MELOXIDYL (meloxicam) oral suspension. Accessed May 9, 2026. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/downloads.regulations.gov\/FDA-2013-N-0002-0027\/content.pdf&ved=2ahUKEwjSp623gqWUAxWeSfEDHdbjOkgQFnoECBcQAQ&usg=AOvVaw3GJIaymUly6w6qm3u0UoRx."},{"key":"ref36","series-title":"UK Vet Companion Animal","article-title":"Identification and possible pathogenesis of bedinvetmab-associated adverse joint events","author":"Armitage A","year":"2026","unstructured":"Armitage A. Identification and possible pathogenesis of bedinvetmab-associated adverse joint events. UK Vet Companion Animal 2026. Accessed May 9, 2026. https:\/\/www.magonlinelibrary.com\/doi\/abs\/10.12968\/coan.2026.0009"},{"key":"ref37","series-title":"Front Vet Sci","first-page":"1558222","article-title":"Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela)","volume":"12","author":"Monteiro BP","year":"2025","unstructured":"Monteiro BP, Simon A, Knesl O,  Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela). Front Vet Sci. 2025;12:1558222. doi:10.3389\/fvets.2025.1558222"},{"issue":"1","key":"ref38","series-title":"Sci Rep","first-page":"5641","article-title":"Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care","volume":"8","author":"Anderson KL","year":"2018","unstructured":"Anderson KL, O\u2019Neill DG, Brodbelt DC,  Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Sci Rep. 2018;8(1):5641. doi:10.1038\/s41598-018-23940-z"},{"key":"ref39","article-title":"Librela (bedinvetmab injection) product package insert","author":"Zoetis","unstructured":"Zoetis. Librela (bedinvetmab injection) product package insert. Accessed May 9, 2026. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/www.zoetisus.com\/content\/_assets\/docs\/vmips\/package-inserts\/librela-prescribing-information.pdf&ved=2ahUKEwjGosepmv6RAxW6SPEDHUC1EvoQFnoECAwQAQ&usg=AOvVaw3SBHdmrH4E6nUYYtfOiCcg"},{"key":"ref40","article-title":"LISTSERV discussion","author":"Retroactive open access (under the author-pays model)","unstructured":"Retroactive open access (under the author-pays model). LISTSERV discussion. Groups.io. Ortholistserv discussion. May 14, 2023-March 23, 2026. Accessed May 9, 2026. https:\/\/groups.io\/g\/Ortholistserv"},{"key":"ref41","article-title":"Librela solution for injection for dogs - SPC update","author":"UK Veterinary Medicines Directorate","unstructured":"UK Veterinary Medicines Directorate. Librela solution for injection for dogs - SPC update. Accessed May 9, 2026. https:\/\/www.gov.uk\/government\/news\/librela-solution-for-injection-for-dogs-spc-update"},{"issue":"3","key":"ref42","series-title":"Vet Anaesth Analg","first-page":"374","article-title":"Answer re: a case of potential rapidly progressing osteoarthritis (RPOA) in a dog under bedinvetmab treatment","volume":"52","author":"Iff I","year":"2025","unstructured":"Iff I, Hohermuth B, Bass D, Bass M. Answer re: a case of potential rapidly progressing osteoarthritis (RPOA) in a dog under bedinvetmab treatment. Vet Anaesth Analg. 2025;52(3):374\u2013375. doi:10.1016\/j.vaa.2025.03.001. Letter."},{"issue":"2","key":"ref43","series-title":"Vet Surg","first-page":"155","article-title":"Does radiographic arthrosis correlate with cartilage pathology in Labrador Retrievers affected by medial coronoid process disease?","volume":"43","author":"Farrell M","year":"2014","unstructured":"Farrell M, Heller J, Solano M,  Does radiographic arthrosis correlate with cartilage pathology in Labrador Retrievers affected by medial coronoid process disease? Vet Surg. 2014;43(2):155\u2013165. doi:10.1111\/j.1532-950X.2014.12092.x"},{"key":"ref44","article-title":"Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 10-12 March 2026","author":"European Medicines Agency","year":"2026","unstructured":"European Medicines Agency. Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 10-12 March 2026. March 13, 2026. Accessed May 9, 2026. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-veterinary-medicinal-products-cvmp-10-12-march-2026"},{"key":"ref45","article-title":"Adverse events and signal detection: bedinvetmab update","author":"Paul-Ehrlich-Institut","unstructured":"Paul-Ehrlich-Institut. Adverse events and signal detection: bedinvetmab update. Accessed May 9, 2026. https:\/\/www.pei.de\/SharedDocs\/Downloads\/EN\/newsroom-en\/notification\/260401-librela-update-product-information.pdf?__blob=publicationFile&v=3"},{"issue":"6","key":"ref46","series-title":"Vet Anaesth Analg","first-page":"943","article-title":"A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis","volume":"48","author":"Corral MJ","year":"2021","unstructured":"Corral MJ, Moyaert H, Fernandes T,  A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021;48(6):943\u2013955. doi:10.1016\/j.vaa.2021.08.001"},{"issue":"5","key":"ref47","series-title":"Vet Anaesth Analg","first-page":"446","article-title":"A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody","volume":"50","author":"Michels GM","year":"2023","unstructured":"Michels GM, Honsberger NA, Walters RR, Kira S Tena J, Cleaver DM. A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. Vet Anaesth Analg. 2023;50(5):446\u2013458. doi:10.1016\/j.vaa.2023.06.003"},{"issue":"2","key":"ref48","series-title":"Vet Radiol Ultrasound","first-page":"143","article-title":"Radiographic progression of osteoarthritis of the canine stifle joint: a prospective study","volume":"45","author":"Innes JF","year":"2004","unstructured":"Innes JF, Costello M, Barr FJ, Rudorf H, Barr AR. Radiographic progression of osteoarthritis of the canine stifle joint: a prospective study. Vet Radiol Ultrasound. 2004;45(2):143\u2013148. doi:10.1111\/j.1740-8261.2004.04024.x"},{"key":"ref49","article-title":"Animal drug safety-related labeling changes: Librela (bedinvetmab injection), NADA 141-562","year":"2025","unstructured":"US FDA. Animal drug safety-related labeling changes: Librela (bedinvetmab injection), NADA 141-562, February 18, 2025. Accessed May 9, 2026. https:\/\/www.fda.gov\/animal-veterinary\/drug-labels\/animal-drug-safety-related-labeling-changes"},{"key":"ref50","article-title":"Librela (bedinvetmab injection): client information sheet","author":"Zoetis","unstructured":"Zoetis. Librela (bedinvetmab injection): client information sheet. Accessed May 9, 2026. https:\/\/www.zoetisus.com\/content\/_assets\/docs\/vmips\/package-inserts\/librela-client-information-sheet.pdf"},{"key":"ref51","series-title":"Vet Times","article-title":"VMD \u2018satisfied\u2019 that Librela benefits outweigh its risks \u2018for vast majority\u2019","author":"Webb A","year":"2026","unstructured":"Webb A. VMD \u2018satisfied\u2019 that Librela benefits outweigh its risks \u2018for vast majority\u2019. Vet Times. February 25, 2026. Accessed May 9, 2026. https:\/\/www.vettimes.com\/news\/vets\/small-animal-vets\/vmd-satisfied-that-librela-benefits-outweigh-its-risks-for-vast-majority"},{"key":"ref52","series-title":"DVM360","article-title":"Judge dismisses class-action lawsuit against Zoetis regarding Librela safety claims","author":"McCafferty C","year":"2025","unstructured":"McCafferty C. Judge dismisses class-action lawsuit against Zoetis regarding Librela safety claims. DVM360. October 22, 2025. Accessed May 9, 2026. http:\/\/www.dvm360.com\/view\/judge-drops-class-action-lawsuit-against-zoetis-over-librela"},{"key":"ref53","article-title":"PLAINTIFFS\u2019 RESPONSE TO DEFENDANT ZOETIS, INC.\u2019S NOTICE OF SUPPLEMENTAL AUTHORITY","author":"Hartney v Zoetis","unstructured":"Hartney v Zoetis. PLAINTIFFS\u2019 RESPONSE TO DEFENDANT ZOETIS, INC.\u2019S NOTICE OF SUPPLEMENTAL AUTHORITY. Case 2:24-cv-09698-SDW-AME. Document 56. Filed 04\/08\/26."},{"issue":"2","key":"ref54","series-title":"Am J Public Health","first-page":"221","article-title":"The promotion and marketing of oxycontin: commercial triumph, public health tragedy","volume":"99","author":"Van Zee A","year":"2009","unstructured":"Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221\u2013227. doi:10.2105\/AJPH.2007.131714"},{"key":"ref55","article-title":"Evolution of adverse event reporting for Librela (bedinvetmab) after the identification of rapidly progressive osteoarthritis","author":"von Pfeil DJF","unstructured":"von Pfeil DJF, Adams RJ. Evolution of adverse event reporting for Librela (bedinvetmab) after the identification of rapidly progressive osteoarthritis. Abstract accepted for: European College of Veterinary Surgeons Annual Scientific Meeting, July 7-11, 2026; Liverpool, UK."},{"key":"ref56","article-title":"Contact us: reporting an adverse event","author":"Zoetis","unstructured":"Zoetis. Contact us: reporting an adverse event. Accessed May 9, 2026. https:\/\/www.zoetis.com\/contact-us"},{"key":"ref57","article-title":"MedWatch: the FDA safety information and adverse event reporting program","unstructured":"US FDA. MedWatch: the FDA safety information and adverse event reporting program. Accessed May 9, 2026. https:\/\/www.fda.gov\/safety\/medwatch-fda-safety-information-and-adverse-event-reporting-program"},{"key":"ref58","article-title":"Report a side effect","author":"Government of Canada","unstructured":"Government of Canada. Report a side effect. Accessed May 9, 2026. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/adverse-reaction-reporting.html"},{"key":"ref59","article-title":"How to report a side effect","author":"EudraVigilance","unstructured":"EudraVigilance. How to report a side effect. Accessed May 9, 2026. https:\/\/www.adrreports.eu\/en\/report_side_effect.html"},{"key":"ref60","article-title":"Report an adverse event or safety problem","author":"Australian Government: Department of Health, Disability, and Ageing","unstructured":"Australian Government: Department of Health, Disability, and Ageing. Report an adverse event or safety problem. Accessed May 9, 2026. https:\/\/www.tga.gov.au\/safety\/report-problem\/report-adverse-event-or-safety-problem"},{"key":"ref61","series-title":"Front Vet Sci","first-page":"1628681","article-title":"Commentary: musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)","volume":"12","author":"Brunke MW","year":"2025","unstructured":"Brunke MW, Dewey CW. Commentary: musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1628681. doi:10.3389\/fvets.2025.1628681"},{"key":"ref62","article-title":"Summary of opinion (initial authorisation)\u2014Lenivia: international non-proprietary name (INN): izenivetmab","author":"European Medicines Agency Committee for Veterinary Medicinal Products","unstructured":"European Medicines Agency Committee for Veterinary Medicinal Products. Summary of opinion (initial authorisation)\u2014Lenivia: international non-proprietary name (INN): izenivetmab. CVMP\/308157\/2025. Accessed May 9, 2026. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/cvmp-summary-positive-opinion-lenivia_en.pdf&ved=2ahUKEwj-kdH5-e2SAxWqJUQIHfc2CzkQFnoECBwQAQ&usg=AOvVaw0OR42Soo22-HO-Ss-gEpDN"},{"key":"ref63","article-title":"Halt approval & commercial release of Lenivia & Portela - Zoetis\u2019 new anti-NGF drugs!","author":"Change.org","unstructured":"Change.org. Halt approval & commercial release of Lenivia & Portela - Zoetis\u2019 new anti-NGF drugs! Accessed May 9, 2026. https:\/\/www.change.org\/p\/halt-approval-commercial-release-of-lenivia-portela-zoetis-new-anti-ngf-drugs"},{"key":"ref1","series-title":"Vet J","first-page":"105733","article-title":"Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs","volume":"276","author":"Krautmann M","year":"2021","unstructured":"Krautmann M, Walters R, Cole P,  Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. Vet J. 2021;276:105733. doi:10.1016\/j.tvjl.2021.105733"},{"key":"ref2","series-title":"Front Vet Sci","first-page":"1502218","article-title":"A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis","volume":"12","author":"Innes JF","year":"2025","unstructured":"Innes JF, Lascelles BDX, Bell D,  A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. Front Vet Sci. 2025;12:1502218. doi:10.3389\/fvets.2025.1502218"},{"issue":"15","key":"ref3","series-title":"Animals (Basel)","first-page":"2231","article-title":"Use of Bedinvetmab (Librela) for canine osteoarthritis in France, Germany, Italy, Spain, and the UK: quantitative analysis of veterinarian satisfaction and real-world treatment patterns","volume":"14","author":"Gildea E","year":"2024","unstructured":"Gildea E, North C, Walker K, Adriaens F, Lascelles BDX. Use of Bedinvetmab (Librela) for canine osteoarthritis in France, Germany, Italy, Spain, and the UK: quantitative analysis of veterinarian satisfaction and real-world treatment patterns. Animals (Basel). 2024;14(15):2231. doi:10.3390\/ani14152231"},{"issue":"3","key":"ref4","series-title":"Curr Neuropharmacol","first-page":"294","article-title":"Nerve growth factor: a focus on neuroscience and therapy","volume":"13","author":"Aloe L","year":"2015","unstructured":"Aloe L, Rocco ML, Balzamino BO, Micera A. Nerve growth factor: a focus on neuroscience and therapy. Curr Neuropharmacol. 2015;13(3):294\u2013303. doi:10.2174\/1570159X13666150403231920"},{"issue":"1","key":"ref5","series-title":"J Transl Med","first-page":"239","article-title":"Nerve growth factor: from the early discoveries to the potential clinical use","volume":"10","author":"Aloe L","year":"2012","unstructured":"Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. 2012;10(1):239. doi:10.1186\/1479-5876-10-239"},{"issue":"6781","key":"ref6","series-title":"Science","first-page":"eadr9608","article-title":"Mapping somatosensory afferent circuitry to bone identifies neurotrophic signals required for fracture healing","volume":"391","author":"Xu M","year":"2026","unstructured":"Xu M, Li Z, Thottappillil N,  Mapping somatosensory afferent circuitry to bone identifies neurotrophic signals required for fracture healing. Science. 2026;391(6781):eadr9608. doi:10.1126\/science.adr9608"},{"issue":"1","key":"ref7","series-title":"Nat Commun","first-page":"3225","article-title":"Nerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints","volume":"15","author":"Zhao L","year":"2024","unstructured":"Zhao L, Lai Y, Jiao H, Huang J. Nerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints. Nat Commun. 2024;15(1):3225. doi:10.1038\/s41467-024-47633-6"},{"issue":"suppl 1","key":"ref8","series-title":"Osteoarthritis Cartilage","first-page":"S18","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23","author":"Hochberg MC","year":"2015","unstructured":"Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015;23(suppl 1):S18\u2013S21. doi:10.1016\/j.joca.2014.10.005"},{"issue":"1","key":"ref9","series-title":"Ann Rheum Dis","first-page":"295","article-title":"Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model","volume":"76","author":"LaBranche TP","year":"2017","unstructured":"LaBranche TP, Bendele AM, Omura BC,  Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Ann Rheum Dis. 2017;76(1):295\u2013302. doi:10.1136\/annrheumdis-2015-208913"},{"key":"ref10","series-title":"Front Physiol","first-page":"1201328","article-title":"Anti-NGF treatment worsens subchondral bone and cartilage measures while improving symptoms in floor-housed rabbits with osteoarthritis","volume":"14","author":"Menges S","year":"2023","unstructured":"Menges S, Michaelis M, Kleinschmidt-D\u00f6rr K. Anti-NGF treatment worsens subchondral bone and cartilage measures while improving symptoms in floor-housed rabbits with osteoarthritis. Front Physiol. 2023;14:1201328. doi:10.3389\/fphys.2023.1201328"},{"key":"ref11","article-title":"Joint meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee. Meeting transcript","year":"2021","unstructured":"US FDA. Joint meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee. Meeting transcript. March 25, 2021. Accessed February 2, 2026. http:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/referrals\/librela"},{"issue":"3","key":"ref12","series-title":"J Orthop","first-page":"260","article-title":"Overlapping features of rapidly progressive osteoarthrosis and Charcot arthropathy","volume":"16","author":"Sono T","year":"2019","unstructured":"Sono T, Meyers CA, Miller D, Ding C, McCarthy EF, James AW. Overlapping features of rapidly progressive osteoarthrosis and Charcot arthropathy. J Orthop. 2019;16(3):260\u2013264. doi:10.1016\/j.jor.2019.02.015"},{"issue":"1","key":"ref13","series-title":"Arthritis Res Ther","first-page":"78","article-title":"Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study","volume":"24","author":"Neogi T","year":"2022","unstructured":"Neogi T, Hunter DJ, Churchill M,  Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study. Arthritis Res Ther. 2022;24(1):78. doi:10.1186\/s13075-022-02759-0"},{"issue":"2","key":"ref14","series-title":"Arthritis Rheumatol","first-page":"382","article-title":"When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program","volume":"68","author":"Hochberg MC","year":"2016","unstructured":"Hochberg MC, Tive LA, Abramson SB,  When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 2016;68(2):382\u2013391. doi:10.1002\/art.39492"},{"issue":"4","key":"ref15","series-title":"Arthritis Rheumatol","first-page":"763","article-title":"Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase II randomized, double-blind, placebo-controlled extension study","volume":"69","author":"Sanga P","year":"2017","unstructured":"Sanga P, Katz N, Polverejan E,  Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase II randomized, double-blind, placebo-controlled extension study. Arthritis Rheumatol. 2017;69(4):763\u2013773. doi:10.1002\/art.39943"},{"key":"ref16","article-title":"Joint meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee. Meeting transcript","year":"2021","unstructured":"US FDA. Joint meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee. Meeting transcript. March 24, 2021. Accessed May 9, 2026. https:\/\/www.fda.gov\/media\/150662\/download"},{"key":"ref17","series-title":"Front Vet Sci","first-page":"1581490","article-title":"Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)","volume":"12","author":"Farrell M","year":"2025","unstructured":"Farrell M, Waibel FWA, Carrera I,  Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1581490. doi:10.3389\/fvets.2025.1581490"},{"issue":"2","key":"ref18","series-title":"Vet Anaesth Analg","first-page":"263","article-title":"A case of potential rapidly progressing osteoarthritis in a dog during bedinvetmab treatment","volume":"52","author":"Iff I","year":"2025","unstructured":"Iff I, Hohermuth B, Bass D, Bass M. A case of potential rapidly progressing osteoarthritis in a dog during bedinvetmab treatment. Vet Anaesth Analg. 2025;52(2):263\u2013265. doi:10.1016\/j.vaa.2024.11.041"},{"key":"ref19","series-title":"Front Vet Sci","first-page":"1640217","article-title":"Rapidly progressive osteoarthritis (RPOA) in companion animals treated with bedinvetmab (Librela): an expected pathophysiological phenomenon or a cause for concern?","volume":"12","author":"Mobasheri A","year":"2025","unstructured":"Mobasheri A, Hanson P, Larkin J. Rapidly progressive osteoarthritis (RPOA) in companion animals treated with bedinvetmab (Librela): an expected pathophysiological phenomenon or a cause for concern? Front Vet Sci. 2025;12:1640217. doi:10.3389\/fvets.2025.1640217"},{"key":"ref20","article-title":"Identification of Librela associated adverse joint events","author":"Armitage A","unstructured":"Armitage A. Identification of Librela associated adverse joint events. Poster presented at: Annual Meeting of the Veterinary Osteoarthritis Alliance; May 21-22, 2025; Loughborough, UK. Accessed May 9, 2026. https:\/\/www.stemcellsscotland.co.uk\/images\/content\/publications\/librela-adverse-reactions.png"},{"issue":"3","key":"ref21","series-title":"Vet Comp Orthop Traumatol","first-page":"157","article-title":"Emerging signs of rapidly progressive arthritic changes in dogs and cats receiving bedinvetmab and frunevetmab","volume":"39","author":"von Pfeil DJF","year":"2026","unstructured":"von Pfeil DJF, Armitage A, Nelson NC. Emerging signs of rapidly progressive arthritic changes in dogs and cats receiving bedinvetmab and frunevetmab. Vet Comp Orthop Traumatol. 2026;39(3):157\u2013161. doi:10.1055\/a-2846-8347"},{"key":"ref22","series-title":"Meeting transcript","article-title":"Arthritis Advisory Committee (AAC) Meeting","year":"2012","unstructured":"US FDA. Arthritis Advisory Committee (AAC) Meeting. Meeting transcript. March 12, 2012. Accessed June 26, 2024. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM307880"},{"key":"ref23","article-title":"Further characterization of a potential musculoskeletal syndrome associated with bedinvetmab in dogs: results from a surgeon questionnaire","author":"Lee BT","unstructured":"Lee BT, Fox DB. Further characterization of a potential musculoskeletal syndrome associated with bedinvetmab in dogs: results from a surgeon questionnaire. Abstract presented at: Annual Veterinary Orthopedic Society Conference; March 14-21, 2026; Big Sky, Montana. Conference proceedings: 10."},{"key":"ref24","article-title":"Dear veterinarian letter notifying veterinarians about adverse events reported in dogs treated with Librela (bedinvetmab injection)","unstructured":"US FDA. Dear veterinarian letter notifying veterinarians about adverse events reported in dogs treated with Librela (bedinvetmab injection). Accessed May 9, 2026. https:\/\/www.fda.gov\/animal-veterinary\/product-safety-information\/dear-veterinarian-letter-notifying-veterinarians-about-adverse-events-reported-dogs-treated-librela"},{"key":"ref25","article-title":"List of changes to combined VeDDRA list of clinical terms","author":"European Medicines Agency","unstructured":"European Medicines Agency. List of changes to combined VeDDRA list of clinical terms. Accessed May 9, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/list-changes-combined-veterinary-dictionary-drug-regulatory-activities-veddra-list-clinical-terms-reporting-suspected-adverse-events-animal-humans-veterinary-medicinal-products-2025_en.pdf"},{"key":"ref26","article-title":"Beransa canine injections-updated labels","author":"Australian Pesticides and Veterinary Medicines Authority","unstructured":"Australian Pesticides and Veterinary Medicines Authority. Beransa canine injections-updated labels. Accessed May 9, 2026. https:\/\/www.apvma.gov.au\/news-and-publications\/statements\/beransa-canine-injections-updated-labels?utm_source=APVMA+Newsletters+and+Communications&utm_campaign=12de21248a-news-update-250808&utm_medium=email&utm_term=0_a025640240-12de21248a-194797373"},{"issue":"16","key":"ref27","series-title":"N Engl J Med","first-page":"1521","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee","volume":"363","author":"Lane NE","year":"2010","unstructured":"Lane NE, Schnitzer TJ, Birbara CA,  Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363(16):1521\u20131531. doi:10.1056\/NEJMoa0901510"},{"issue":"1","key":"ref28","series-title":"Anesthesiology","first-page":"189","article-title":"Antagonism of nerve growth factor-TrkA signaling and the relief of pain","volume":"115","author":"Mantyh PW","year":"2011","unstructured":"Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL, Warner DS. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115(1):189\u2013204. doi:10.1097\/ALN.0b013e31821b1ac5"},{"issue":"12","key":"ref29","series-title":"Osteoarthritis Cartilage","first-page":"1612","article-title":"Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab","volume":"31","author":"Carrino JA","year":"2023","unstructured":"Carrino JA, McAlindon TE, Schnitzer TJ,  Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab. Osteoarthritis Cartilage. 2023;31(12):1612\u20131626. doi:10.1016\/j.joca.2023.08.010"},{"key":"ref30","series-title":"Ther Adv Musculoskelet Dis","first-page":"1759720x231171768","article-title":"Role of imaging for eligibility and safety of a-NGF clinical trials","volume":"15","author":"Roemer FW","year":"2023","unstructured":"Roemer FW, Hochberg MC, Carrino JA,  Role of imaging for eligibility and safety of a-NGF clinical trials. Ther Adv Musculoskelet Dis. 2023;15:1759720x231171768. doi:10.1177\/1759720X231171768"},{"issue":"9","key":"ref31","series-title":"Pain","first-page":"2068","article-title":"Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety","volume":"161","author":"Markman JD","year":"2020","unstructured":"Markman JD, Bolash RB, McAlindon TE,  Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain. 2020;161(9):2068\u20132078. doi:10.1097\/j.pain.0000000000001928"},{"issue":"12","key":"ref32","series-title":"Clin J Pain","first-page":"914","article-title":"Relative efficacy and safety of tanezumab for osteoarthritis: a systematic review and meta-analysis of randomized-controlled trials","volume":"37","author":"Zhang B","year":"2021","unstructured":"Zhang B, Tian X, Qu Z, Liu J, Yang L. Relative efficacy and safety of tanezumab for osteoarthritis: a systematic review and meta-analysis of randomized-controlled trials. Clin J Pain. 2021;37(12):914\u2013924. doi:10.1097\/AJP.0000000000000986"},{"issue":"3","key":"ref33","series-title":"Vet Anaesth Analg","first-page":"371","article-title":"A case of potential rapidly progressing osteoarthritis (RPOA) in a dog during bedinvetmab treatment. Veterinary Anaesthesia and Analgesia. 2024 Nov 29. Letter","volume":"52","author":"Farrell M","year":"2025","unstructured":"Farrell M, Adams R, Clark L. Iff I, Hohermuth B, Bass D, Bass M. A case of potential rapidly progressing osteoarthritis (RPOA) in a dog during bedinvetmab treatment. Veterinary Anaesthesia and Analgesia. 2024 Nov 29. Letter. Vet Anaesth Analg. 2025;52(3):371\u2013372. doi:10.1016\/j.vaa.2025.02.013"},{"key":"ref34","article-title":"CVM GFI #185 (VICH GL43): Target animal safety for veterinary pharmaceutical products","unstructured":"US FDA. CVM GFI #185 (VICH GL43): Target animal safety for veterinary pharmaceutical products. Accessed May 9, 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-185-vich-gl43-target-animal-safety-veterinary-pharmaceutical-products"},{"key":"ref35","author":"Freedom of Information summary: original new animal drug application\u2014MELOXIDYL (meloxicam) oral suspension","unstructured":"Freedom of Information summary: original new animal drug application\u2014MELOXIDYL (meloxicam) oral suspension. Accessed May 9, 2026. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/downloads.regulations.gov\/FDA-2013-N-0002-0027\/content.pdf&ved=2ahUKEwjSp623gqWUAxWeSfEDHdbjOkgQFnoECBcQAQ&usg=AOvVaw3GJIaymUly6w6qm3u0UoRx."},{"key":"ref36","series-title":"UK Vet Companion Animal","article-title":"Identification and possible pathogenesis of bedinvetmab-associated adverse joint events","author":"Armitage A","year":"2026","unstructured":"Armitage A. Identification and possible pathogenesis of bedinvetmab-associated adverse joint events. UK Vet Companion Animal 2026. Accessed May 9, 2026. https:\/\/www.magonlinelibrary.com\/doi\/abs\/10.12968\/coan.2026.0009"},{"key":"ref37","series-title":"Front Vet Sci","first-page":"1558222","article-title":"Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela)","volume":"12","author":"Monteiro BP","year":"2025","unstructured":"Monteiro BP, Simon A, Knesl O,  Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela). Front Vet Sci. 2025;12:1558222. doi:10.3389\/fvets.2025.1558222"},{"issue":"1","key":"ref38","series-title":"Sci Rep","first-page":"5641","article-title":"Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care","volume":"8","author":"Anderson KL","year":"2018","unstructured":"Anderson KL, O\u2019Neill DG, Brodbelt DC,  Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Sci Rep. 2018;8(1):5641. doi:10.1038\/s41598-018-23940-z"},{"key":"ref39","article-title":"Librela (bedinvetmab injection) product package insert","author":"Zoetis","unstructured":"Zoetis. Librela (bedinvetmab injection) product package insert. Accessed May 9, 2026. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/www.zoetisus.com\/content\/_assets\/docs\/vmips\/package-inserts\/librela-prescribing-information.pdf&ved=2ahUKEwjGosepmv6RAxW6SPEDHUC1EvoQFnoECAwQAQ&usg=AOvVaw3SBHdmrH4E6nUYYtfOiCcg"},{"key":"ref40","article-title":"LISTSERV discussion","author":"Retroactive open access (under the author-pays model)","unstructured":"Retroactive open access (under the author-pays model). LISTSERV discussion. Groups.io. Ortholistserv discussion. May 14, 2023-March 23, 2026. Accessed May 9, 2026. https:\/\/groups.io\/g\/Ortholistserv"},{"key":"ref41","article-title":"Librela solution for injection for dogs - SPC update","author":"UK Veterinary Medicines Directorate","unstructured":"UK Veterinary Medicines Directorate. Librela solution for injection for dogs - SPC update. Accessed May 9, 2026. https:\/\/www.gov.uk\/government\/news\/librela-solution-for-injection-for-dogs-spc-update"},{"issue":"3","key":"ref42","series-title":"Vet Anaesth Analg","first-page":"374","article-title":"Answer re: a case of potential rapidly progressing osteoarthritis (RPOA) in a dog under bedinvetmab treatment","volume":"52","author":"Iff I","year":"2025","unstructured":"Iff I, Hohermuth B, Bass D, Bass M. Answer re: a case of potential rapidly progressing osteoarthritis (RPOA) in a dog under bedinvetmab treatment. Vet Anaesth Analg. 2025;52(3):374\u2013375. doi:10.1016\/j.vaa.2025.03.001. Letter."},{"issue":"2","key":"ref43","series-title":"Vet Surg","first-page":"155","article-title":"Does radiographic arthrosis correlate with cartilage pathology in Labrador Retrievers affected by medial coronoid process disease?","volume":"43","author":"Farrell M","year":"2014","unstructured":"Farrell M, Heller J, Solano M,  Does radiographic arthrosis correlate with cartilage pathology in Labrador Retrievers affected by medial coronoid process disease? Vet Surg. 2014;43(2):155\u2013165. doi:10.1111\/j.1532-950X.2014.12092.x"},{"key":"ref44","article-title":"Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 10-12 March 2026","author":"European Medicines Agency","year":"2026","unstructured":"European Medicines Agency. Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 10-12 March 2026. March 13, 2026. Accessed May 9, 2026. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-veterinary-medicinal-products-cvmp-10-12-march-2026"},{"key":"ref45","article-title":"Adverse events and signal detection: bedinvetmab update","author":"Paul-Ehrlich-Institut","unstructured":"Paul-Ehrlich-Institut. Adverse events and signal detection: bedinvetmab update. Accessed May 9, 2026. https:\/\/www.pei.de\/SharedDocs\/Downloads\/EN\/newsroom-en\/notification\/260401-librela-update-product-information.pdf?__blob=publicationFile&v=3"},{"issue":"6","key":"ref46","series-title":"Vet Anaesth Analg","first-page":"943","article-title":"A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis","volume":"48","author":"Corral MJ","year":"2021","unstructured":"Corral MJ, Moyaert H, Fernandes T,  A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021;48(6):943\u2013955. doi:10.1016\/j.vaa.2021.08.001"},{"issue":"5","key":"ref47","series-title":"Vet Anaesth Analg","first-page":"446","article-title":"A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody","volume":"50","author":"Michels GM","year":"2023","unstructured":"Michels GM, Honsberger NA, Walters RR, Kira S Tena J, Cleaver DM. A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. Vet Anaesth Analg. 2023;50(5):446\u2013458. doi:10.1016\/j.vaa.2023.06.003"},{"issue":"2","key":"ref48","series-title":"Vet Radiol Ultrasound","first-page":"143","article-title":"Radiographic progression of osteoarthritis of the canine stifle joint: a prospective study","volume":"45","author":"Innes JF","year":"2004","unstructured":"Innes JF, Costello M, Barr FJ, Rudorf H, Barr AR. Radiographic progression of osteoarthritis of the canine stifle joint: a prospective study. Vet Radiol Ultrasound. 2004;45(2):143\u2013148. doi:10.1111\/j.1740-8261.2004.04024.x"},{"key":"ref49","article-title":"Animal drug safety-related labeling changes: Librela (bedinvetmab injection), NADA 141-562","year":"2025","unstructured":"US FDA. Animal drug safety-related labeling changes: Librela (bedinvetmab injection), NADA 141-562, February 18, 2025. Accessed May 9, 2026. https:\/\/www.fda.gov\/animal-veterinary\/drug-labels\/animal-drug-safety-related-labeling-changes"},{"key":"ref50","article-title":"Librela (bedinvetmab injection): client information sheet","author":"Zoetis","unstructured":"Zoetis. Librela (bedinvetmab injection): client information sheet. Accessed May 9, 2026. https:\/\/www.zoetisus.com\/content\/_assets\/docs\/vmips\/package-inserts\/librela-client-information-sheet.pdf"},{"key":"ref51","series-title":"Vet Times","article-title":"VMD \u2018satisfied\u2019 that Librela benefits outweigh its risks \u2018for vast majority\u2019","author":"Webb A","year":"2026","unstructured":"Webb A. VMD \u2018satisfied\u2019 that Librela benefits outweigh its risks \u2018for vast majority\u2019. Vet Times. February 25, 2026. Accessed May 9, 2026. https:\/\/www.vettimes.com\/news\/vets\/small-animal-vets\/vmd-satisfied-that-librela-benefits-outweigh-its-risks-for-vast-majority"},{"key":"ref52","series-title":"DVM360","article-title":"Judge dismisses class-action lawsuit against Zoetis regarding Librela safety claims","author":"McCafferty C","year":"2025","unstructured":"McCafferty C. Judge dismisses class-action lawsuit against Zoetis regarding Librela safety claims. DVM360. October 22, 2025. Accessed May 9, 2026. http:\/\/www.dvm360.com\/view\/judge-drops-class-action-lawsuit-against-zoetis-over-librela"},{"key":"ref53","article-title":"PLAINTIFFS\u2019 RESPONSE TO DEFENDANT ZOETIS, INC.\u2019S NOTICE OF SUPPLEMENTAL AUTHORITY","author":"Hartney v Zoetis","unstructured":"Hartney v Zoetis. PLAINTIFFS\u2019 RESPONSE TO DEFENDANT ZOETIS, INC.\u2019S NOTICE OF SUPPLEMENTAL AUTHORITY. Case 2:24-cv-09698-SDW-AME. Document 56. Filed 04\/08\/26."},{"issue":"2","key":"ref54","series-title":"Am J Public Health","first-page":"221","article-title":"The promotion and marketing of oxycontin: commercial triumph, public health tragedy","volume":"99","author":"Van Zee A","year":"2009","unstructured":"Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221\u2013227. doi:10.2105\/AJPH.2007.131714"},{"key":"ref55","article-title":"Evolution of adverse event reporting for Librela (bedinvetmab) after the identification of rapidly progressive osteoarthritis","author":"von Pfeil DJF","unstructured":"von Pfeil DJF, Adams RJ. Evolution of adverse event reporting for Librela (bedinvetmab) after the identification of rapidly progressive osteoarthritis. Abstract accepted for: European College of Veterinary Surgeons Annual Scientific Meeting, July 7-11, 2026; Liverpool, UK."},{"key":"ref56","article-title":"Contact us: reporting an adverse event","author":"Zoetis","unstructured":"Zoetis. Contact us: reporting an adverse event. Accessed May 9, 2026. https:\/\/www.zoetis.com\/contact-us"},{"key":"ref57","article-title":"MedWatch: the FDA safety information and adverse event reporting program","unstructured":"US FDA. MedWatch: the FDA safety information and adverse event reporting program. Accessed May 9, 2026. https:\/\/www.fda.gov\/safety\/medwatch-fda-safety-information-and-adverse-event-reporting-program"},{"key":"ref58","article-title":"Report a side effect","author":"Government of Canada","unstructured":"Government of Canada. Report a side effect. Accessed May 9, 2026. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/adverse-reaction-reporting.html"},{"key":"ref59","article-title":"How to report a side effect","author":"EudraVigilance","unstructured":"EudraVigilance. How to report a side effect. Accessed May 9, 2026. https:\/\/www.adrreports.eu\/en\/report_side_effect.html"},{"key":"ref60","article-title":"Report an adverse event or safety problem","author":"Australian Government: Department of Health, Disability, and Ageing","unstructured":"Australian Government: Department of Health, Disability, and Ageing. Report an adverse event or safety problem. Accessed May 9, 2026. https:\/\/www.tga.gov.au\/safety\/report-problem\/report-adverse-event-or-safety-problem"},{"key":"ref61","series-title":"Front Vet Sci","first-page":"1628681","article-title":"Commentary: musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)","volume":"12","author":"Brunke MW","year":"2025","unstructured":"Brunke MW, Dewey CW. Commentary: musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1628681. doi:10.3389\/fvets.2025.1628681"},{"key":"ref62","article-title":"Summary of opinion (initial authorisation)\u2014Lenivia: international non-proprietary name (INN): izenivetmab","author":"European Medicines Agency Committee for Veterinary Medicinal Products","unstructured":"European Medicines Agency Committee for Veterinary Medicinal Products. Summary of opinion (initial authorisation)\u2014Lenivia: international non-proprietary name (INN): izenivetmab. CVMP\/308157\/2025. Accessed May 9, 2026. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/cvmp-summary-positive-opinion-lenivia_en.pdf&ved=2ahUKEwj-kdH5-e2SAxWqJUQIHfc2CzkQFnoECBwQAQ&usg=AOvVaw0OR42Soo22-HO-Ss-gEpDN"},{"key":"ref63","article-title":"Halt approval & commercial release of Lenivia & Portela - Zoetis\u2019 new anti-NGF drugs!","author":"Change.org","unstructured":"Change.org. Halt approval & commercial release of Lenivia & Portela - Zoetis\u2019 new anti-NGF drugs! Accessed May 9, 2026. https:\/\/www.change.org\/p\/halt-approval-commercial-release-of-lenivia-portela-zoetis-new-anti-ngf-drugs"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/aop\/javma.26.03.0170\/javma.26.03.0170.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/aop\/javma.26.03.0170\/javma.26.03.0170.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/aop\/javma.26.03.0170\/javma.26.03.0170.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:45:53Z","timestamp":1782503153000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/aop\/javma.26.03.0170\/javma.26.03.0170.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":126,"URL":"https:\/\/doi.org\/10.2460\/javma.26.03.0170","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}